On Friday, Shares of Facebook, Inc. (NASDAQ:FB), gained 1.06% to $94.42.
Billionaire investor George Soros took a new stake in Time Warner Cable added shares of Facebook Inc. and unloaded most of his stake in Alibaba Group Holding in the second quarter, according to a 13F filing with the Securities and Exchange Commission on Friday. Soros bought nearly 2.5 million shares of Facebook worth $222.3 million as of June 30 and purchased 1.45 million shares of Time Warner Cable worth $259.2 million, according to filing-tracking firm Whalewisdom.com. Soros Fund Administration also sold nearly 4.4 million shares of Chinese e-commerce Firm Alibaba, almost its entire stake, Market Watch Reports.
Facebook, Inc. operates as a social networking company worldwide. It provides a set of development tools and application programming interfaces that enable developers to integrate with Facebook to create mobile and Web applications.
Shares of Aspen Technology, Inc. (NASDAQ:AZPN), declined -10.12% to $37.76, during its last trading session.
Aspen Technology declared financial results for its fourth quarter and fiscal year ended June 30, 2015.
Fourth Quarter and Fiscal Year 2015 Business Highlights
- The license portion of total contract value was $2.07 billion at the end of fiscal 2015, which raised 2.2% from March 31, 2015 and 11.8% contrast to the end of fiscal 2014.
- Total contract value, counting the value of bundled maintenance, was $2.46 billion at the end of fiscal 2015, which raised 2.2% from March 31, 2015 and 12.3% contrast to the end of fiscal 2014.
- Annual spend, which the company defines as the annualized value of all term license and term maintenance contracts at the end of the quarter, was $419 million at the end of fiscal 2015, an enhance of 1.9% from March 31, 2015 and 10.5% from the end of fiscal 2014.
- GAAP operating margin was 41.1%, contrast to 36.8% in the fourth quarter of fiscal 2014. Non-GAAP operating margin was 44.2%, contrast to 39.9% in the fourth quarter of fiscal 2014.
Aspen Technology, Inc., together with its auxiliaries, provides mission-critical process optimization software solutions in the United States, Europe, and internationally. It operates through two segments, Subscription and Software, and Services.
Finally, Incyte Corporation (NASDAQ:INCY), ended its last trade with -1.96% loss, and closed at $105.80.
Incyte Corporation stated 2015 second-quarter financial results, counting revenue from Jakafi.
The Company highlighted the continued momentum in the commercialization of Jakafi in the U.S., in addition to progress being made across its clinical portfolio, counting the results of two pivotal trials of baricitinib that were presented with Eli Lilly and Company (“Lilly”) at the 2015 European League Against Rheumatism (EULAR) meeting in June. In addition, positive proof-of-concept results from the novel:novel combination of Incyte’s PI3Kδ inhibitor INCB40093 and JAK1-selective inhibitor INCB39110 in B-cell malignancies were presented at both the 2015 American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) annual meetings in the second quarter of 2015.
Jakafi is approved by the U.S. Food and Drug Administration for treatment of people with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea. Jakafi is also indicated for treatment of people with intermediate or high-risk myelofibrosis (MF), counting primary MF, post–polycythemia vera MF, and post–essential thrombocythemia MF.
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics primarily for oncology.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
